Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study - Wang, Michael; Ramchandren, Radhakrishnan; Chen, Robert; Karlin, Lionel; Chong, Geoffrey; Jurczak, Wojciech; Wu, Ka Lung; Bishton, Mark; Collins, Graham P.; Eliadis, Paul; Peyrade, Frédéric; Lee, Yihua; et al. (Journal of hematology and oncology, 2021)
Keywords: Antimitotic agents; Antineoplastic agents; Apoptosis; Blood; Blood cancer; Bone marrow; Cardiac arrhythmia; Creatinine; Development and progression; Hematological cancers/lymphomas; Hematology; Ibrutinib; Inhibitor drugs; Laboratories; Leukemia; Lymphoma; Lysis; Mantle cell lymphoma; Neutropenia; Non-Hodgkin's lymphomas; Oncology; Patients; Potassium; Rapid Communication; Safety; Safety and security measures; Small molecule agents/kinase inhibitors; Targeted cancer therapy; Tumors; Venetoclax; United States--US